These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 32652621)

  • 1. COVID-19 and Rural Harm Reduction Challenges in the US Southern Mountains.
    Ostrach B; Buer LM; Armbruster S; Brown H; Yochym G; Zaller N
    J Rural Health; 2021 Jan; 37(1):252-255. PubMed ID: 32652621
    [No Abstract]   [Full Text] [Related]  

  • 2. Health literacy and changes in pattern of drug use among participants at the Stockholm Needle Exchange Program during the COVID-19 pandemic.
    Lindqvist K; Wallmofeldt C; Holmén E; Hammarberg A; Kåberg M
    Harm Reduct J; 2021 May; 18(1):52. PubMed ID: 33971892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of COVID-19 public health measures on attendance and overdose at supervised injecting facilities in Australia.
    Roxburgh A; Livingston M; Dietze P; Nielsen S; Cogger S; Bartlett M; Day C; Latimer J; Jauncey M; Clark N
    Public Health; 2023 Nov; 224():90-97. PubMed ID: 37742585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Syringe services program (SSP) operational changes during the COVID-19 global outbreak.
    Bartholomew TS; Nakamura N; Metsch LR; Tookes HE
    Int J Drug Policy; 2020 Sep; 83():102821. PubMed ID: 32591222
    [No Abstract]   [Full Text] [Related]  

  • 5. Adapting harm reduction services during COVID-19: lessons from the supervised injecting facilities in Australia.
    Roxburgh A; Jauncey M; Day C; Bartlett M; Cogger S; Dietze P; Nielsen S; Latimer J; Clark N
    Harm Reduct J; 2021 Feb; 18(1):20. PubMed ID: 33596940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Impact of the COVID-19 Pandemic on Drug Use Behaviors, Fentanyl Exposure, and Harm Reduction Service Support among People Who Use Drugs in Rural Settings.
    Bolinski RS; Walters S; Salisbury-Afshar E; Ouellet LJ; Jenkins WD; Almirol E; Van Ham B; Fletcher S; Johnson C; Schneider JA; Ompad D; Pho MT
    Int J Environ Res Public Health; 2022 Feb; 19(4):. PubMed ID: 35206421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Program Adaptations to Provide Harm Reduction Services During the COVID-19 Pandemic: A Qualitative Study of Syringe Services Programs in the U.S.
    Frost MC; Sweek EW; Austin EJ; Corcorran MA; Juarez AM; Frank ND; Prohaska SM; LaKosky PA; Asher AK; Broz D; Jarlais DCD; Williams EC; Glick SN
    AIDS Behav; 2022 Jan; 26(1):57-68. PubMed ID: 34110506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Telehealth in Response to the COVID-19 Pandemic in Rural Veteran and Military Beneficiaries.
    Shura RD; Brearly TW; Tupler LA
    J Rural Health; 2021 Jan; 37(1):200-204. PubMed ID: 32402128
    [No Abstract]   [Full Text] [Related]  

  • 9. Care during COVID-19: Drug use, harm reduction, and intimacy during a global pandemic.
    Schlosser A; Harris S
    Int J Drug Policy; 2020 Sep; 83():102896. PubMed ID: 32768156
    [No Abstract]   [Full Text] [Related]  

  • 10. Rapid Scale-Up of Telehealth During the COVID-19 Pandemic and Implications for Subspecialty Care in Rural Areas.
    Nagata JM
    J Rural Health; 2021 Jan; 37(1):145. PubMed ID: 32246490
    [No Abstract]   [Full Text] [Related]  

  • 11. Evaluation of an Unsanctioned Safe Consumption Site in the United States.
    Kral AH; Lambdin BH; Wenger LD; Davidson PJ
    N Engl J Med; 2020 Aug; 383(6):589-590. PubMed ID: 32640126
    [No Abstract]   [Full Text] [Related]  

  • 12. Telemedicine Services During COVID-19: Considerations for Medically Underserved Populations.
    Woodall T; Ramage M; LaBruyere JT; McLean W; Tak CR
    J Rural Health; 2021 Jan; 37(1):231-234. PubMed ID: 32613657
    [No Abstract]   [Full Text] [Related]  

  • 13. Telehealth Policies Impacting Federally Qualified Health Centers in Face of COVID-19.
    Sodhi M
    J Rural Health; 2021 Jan; 37(1):158-160. PubMed ID: 32277779
    [No Abstract]   [Full Text] [Related]  

  • 14. Integrating Telemedicine for Medication Treatment for Opioid Use Disorder in Rural Primary Care: Beyond the COVID Pandemic.
    Hser YI; Mooney LJ
    J Rural Health; 2021 Jan; 37(1):246-248. PubMed ID: 32579751
    [No Abstract]   [Full Text] [Related]  

  • 15. The Importance of Video Visits in the Time of COVID-19.
    Lindsay JA; Hogan JB; Ecker AH; Day SC; Chen P; Helm A
    J Rural Health; 2021 Jan; 37(1):242-245. PubMed ID: 32506751
    [No Abstract]   [Full Text] [Related]  

  • 16. New hope for unsanctioned safe injection site.
    Glauser W
    CMAJ; 2018 Jan; 190(3):E90-E91. PubMed ID: 29358208
    [No Abstract]   [Full Text] [Related]  

  • 17. Harm Reduction and Adaptations Among PWUD in Rural Oregon During COVID-19.
    Seaman A; Leichtling G; Stack E; Gray M; Pope J; Larsen JE; Leahy JM; Gelberg L; Korthuis PT
    AIDS Behav; 2021 May; 25(5):1331-1339. PubMed ID: 33471243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Primary Care Response to COVID-19 for Patients with an Opioid Use Disorder.
    Wilson CG; Ramage M; Fagan EB
    J Rural Health; 2021 Jan; 37(1):169-171. PubMed ID: 32277732
    [No Abstract]   [Full Text] [Related]  

  • 19. The future of harm reduction programmes in Russia.
    Lancet; 2009 Oct; 374(9697):1213. PubMed ID: 19819371
    [No Abstract]   [Full Text] [Related]  

  • 20. Commentary on Fraser et al. (2018): Evidence base for harm reduction services-the urban-rural divide.
    Lancaster KE; Malvestutto CD; Miller WC; Go VF
    Addiction; 2018 Jan; 113(1):183-184. PubMed ID: 29226535
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.